DOCSLIB.ORG

Time.Com VOL

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Time.Com VOL OCTOBER 29, 2018 time.com VOL. 192, NO. 17 | 2018 4 | Conversation TheView Features △ 6 | For the Record TimeOf Carolyn Eberly, Ideas, opinion, What to watch, read, innovations Democrats’ Deep Roots see and do left, and Ava TheBrief Inside the movement that Williamson, right, News from the U.S. 17 | Eric Holder on | isremaking the party 53 Melissa visit a home in and around the world the consequences of McCarthy turns to South Charlotte, By Charlotte Alter22 7 | Airmative voter suppression the dark side N.C., where they action on trial canvassed for 20 | Ian Bremmer: The Heartland Strategy 56 | What to stream Dan McCready, a 11 | Remembering Japans calculus To retake Congress, Democrats for Halloween Democrat running Microsoft in the China-U.S. focus on the Midwest for Congress, on trade war 57 | Paul Dano co-founder By Philip Elliott29 Sept. 26 Paul Allen discusses his 20 | Remember directorial debut, Photograph by 12 | TIME with ... the PalmPilot? Health Care 50 Wildlife, starring Dina Litovsky— Redux for TIME unlikely newsmaker What a new and The most inluential people Jake Gyllenhaal Stormy Daniels unimproved version in health care By TIME staf33 says about the 60 | 9 Questions 14 | Digging out smartphone market The Pariah Prince for historian after Hurricane Joseph J. Ellis ON THE COVER: Michael The disappearance of journalist Photo- Jamal Khashoggi undoes the image illustration by of a Saudi scionBy Karl Vick42 Pablo Delcan for TIME. Asia’s #MeToo Movement Stickers: A rallying cry spreads across the Jenue; continentBy Suyin Haynes, Aria Trump: Drew Angerer— Hangyu Chen48 Getty Images TIME (ISSN 0040-781X) is published weekly, except for two skipped weeks in January and one skipped week in March, May, July, August, September and December due to combined issues by Time Inc., a wholly owned subsidiary of Meredith Corporation. PRINCIPAL OFFICE: 225 Liberty Street, New York, NY 10281-1008. Periodicals postage paid at New York, N.Y., and additional mailing ofices. POSTMASTER: S e n d a l l U A A t o C F S (S e e D M M 5 07. 1 . 5 . 2); Non-Postal and Military Facilities: send address corrections to TIME Magazine, P.O. Box 62120, Tampa, F L 33662-2120. Canada Post Publications Mail A greement No. 40110178. Return undeliverable Canadian addresses to: Postal Station A, P.O. Box 4322, Toronto, Ontario M5W 3G9. GST No. 888381621RT0001. © 2018 Time Inc. All rights reserved. Reproduction in whole or in part without written permission is prohibited. TIME and the Red Border Design are protected through trademark registration in the United States and in the foreign countries where TIME magazine circulates. U.S. Subscriptions: $49 for one year. SUBSCRIBERS: If the Postal Service REDUX alerts us that your magazine is undeliverable, we have no further obligation unless we receive a corrected address within two years. Your bank may provide updates to the card information we have on ile. You may opt out of this service at any time. CUSTOMER SERVICE AND SUBSCRIPTIONS: For 24/7 service, visit time.com/customerservice. You can also call 1-800-843-TIME; write to TIME, P.O. Box 62120, Tampa, FL, 33662-2120; or email [email protected]. MAILING LIST: We make a portion of our mailing list available to reputable irms. If you would prefer that we not include your name, please call or write us. PRINTED IN THE U.S. XXXXXXX 2 TIME October 29, 2018 “I keep driving breakthroughs forward so my cancer won’t come back.” Maysoun / Breast Cancer Researcher Jessica / Breast Cancer Patient With one in eight women diagnosed with breast cancer in her lifetime, researchers are accelerating new, highly targeted combination therapies that attack cancer cells more precisely and completely, raising the success level of treatment. This is the future of medicine. For all of us. GoBoldly.com Conversation WHAT YOU SAID ABOUT... TRUMPISM BEYOND TRUMP Several readers wrote that they were spooked by the Oct. 22 cover illustration that showed many future elections’ worth of Trump lawn signs, as a metaphor for how the President’s ideology will endure. Michael Morris of Hamden, Conn., called it the ‘Must have scariest TIME cover been TIME’s since “Is God Dead?” Halloween in 1966, and Michelle issue ... The NEW SOUTHERN PHOTOGRAPHY TIME.com spotlights two Szabo of Austin said scariest recently opened exhibitions—at the Ogden Museum of Southern Art she was worried cover I have in New Orleans and South Carolina’s Halsey Institute of Contemporary Art at the College of Charleston—that show how contemporary Trump would con- ever seen!’ photographers (like Susan Worsham, whose 2009 photo of a sider the image an JOYCE DUDASH, Richmond, Va., Marine is above) are capturing the changing endorsement for a Lorain, Ohio American South. See more at time.com/south-photos perpetual presidency. But Mitchell Hall of Cambridge, Mass., tweeted that the cover story by Sam Tanenhaus was an “encourag- bonus ing” one. Tab Lyn Uno of Clearield, Utah, ar- TIME gued that Democratic candidates would ben- politics eit from incorporating more of the economic populism that the story described into their Subscribe to platforms too, for they “have overlooked the TIME’s free politics importance of the white, male worker.” newsletter and get MUSIC British pop star Charli XCX recently exclusive news and insights from NEXT GENERATION LEADERS The Oct. 22 spoke to TIME.com about her rise to fame. “The music I’ve made has allowed me to Washington, sent global TIME covers featured members of the be who I want to be,” she said. “It deinitely straight to your inbox. latest cohort of Next Generation Leaders— took me time to ind out who that was.” For more, visit time. including one with the K-pop band BTS, Watch at time.com/charli-xcx-video com/politicsemail whose legions of fans shared the image ‘It was with millions of fol- SETTING THE RECORD STRAIGHT ▶ In the Brief (Oct. 22), we misspelled an honor lowers. Jimmy Fallon the surname of Nigerian presidential candidate Atiku Abubakar. and joy to held up the cover fea- SUSAN WORSHAM—HALSEY INSTITUTE OF CONTEMPORARY ART TALK TO US work with turing actor-activist ▽ ▽ @amandla Amandla Stenberg SEND AN EMAIL: FOLLOW US: stenberg ... when he interviewed [email protected] facebook.com/time Her @time her on Oct. 10, and Please do not send attachments @time (Twitter and Instagram) has come the French press cel- ebrated the cover Letters should includethewriter’sfullname,addressandhome RUSSELL HORNSBY, photo of soccer star telephone and may be edited for purposes of clarity and space who stars with Stenberg in Kylian Mbappé, who The Hate U Give led France to the 2018 Back Issues Contact us at [email protected] or World Cup champion- call 1-800-274-6800. Reprints and Permissions Information is available at time.com/reprints. To request custom reprints, Advertising ship. Journalist Axel visit timereprints.com. For advertising rates and Please recycle this Roux joked that he should run for President our editorial calendar, visit timemediakit.com. Syndication magazine and remove For international licensing and syndication requests, visit inserts or samples of France: “#Mbappé2022.” timeinc.com/syndication. before recycling Pearl Seas Cruises® K 9 I9X6KXKKW9 B9X/99$ !; # $ % # ™ Baie-Comeau Saguenay Fjord Gaspé Percé Îles de la Madeleine Québec City Charlottetown Montreal Thousand Halifax Islands Bar Harbor Clayton Lunenburg TORONTO PORTLAND QQD] :AAA>B=B?@< 9Q9 K 9 /]W K 9K69 For the Record ‘Australia should be open- ‘NO minded to this, and $630,000 I am open- Value of the stamps a New minded LAUGHING Orleans post office manager is accused of stealing, in to this.’ what authorities are calling one of the Postal Service’s SCOTT MORRISON, largest-ever internal thefts Australian Prime Minister, on moving his country’s embassy in Israel from MATTER.’ Tel Aviv to Jerusalem, as the U.S. did earlier this year THE CITY OF SAVANNAH, GA., in a Facebook post, after a vandal stuck googly eyes on its C, statue of Revolutionary War General Nathanael Greene 60% '21 7 Approximate percentage 7+,1. of Americans of European descent whose DNA could be identifiable through genealogy ,7 6 $ sites even if they aren’t registered users, according to a study in Science +2$; DONALD TRUMP, U.S. President, in an Oct. 14 ‘I think one 60 Minutes interview, reversing his earlier stated C,ORYHKLP view on climate change; “I has to regard don’t know that it’s man- WRGHDWK made,” he added, despite this as a victory overwhelming scientiic 3DUW\GRHVQ W consensus that it is VHSDUDWHXV for humanity MICHELLE OBAMA, asawhole.’ American cheese former U.S. First Lady, on Processed-cheese PIERRE KOMPANY, her friendship with former sales fall as mayor-elect of the Brussels borough of Ganshoren; President George W. Bush; consumers seek out a Congolese refugee who in 1975 led a country protocol dictates that they more natural dairy are often seated next to each that was once under ruthless Belgian colonial other at oficial functions control, he will be the irst black mayor in Belgium ILLUSTRATIONS BY BROWN BIRD DESIGN FOR TIME BAD WEEK 70 GOOD WEEK Approximate number of stray cats that Cream cheese Svetlana Logunova cares for as the new Apple adds a official guardian of homeless felines schmear to the in Zelenogradsk, Russia; her monthly bagel emoji, per budget for the task is about $85 users’ suggestions 6 TIME October 29, 2018 SOURCES: AP; BLOOMBERG; DOJ; GUARDIAN AUSTRALIA; NEW YORK TIMES; REUTERS; USA TODAY THE OLD COLLEGE TRY A demonstrator displays placards outside a courthouse in Boston on Oct. 15 INSIDE THE VATICAN SHOWS SMALL MISS IRAQ 2015 FLEES HER MICROSOFT CO-FOUNDER SIGNS OF CHANGE IN APPROACH COUNTRY AMID HIGH-PROFILE PAUL ALLEN LEAVES BEHIND TO ITS SEX-ABUSE CRISIS ATTACKS ON WOMEN A MULTIFACETED LEGACY PHOTOGRAPH BY LIU JIE TheBrief Opener EDUCATION airmative-action eforts.
Load more

Recommended publications
  • Guardant Health, Inc. Form 8-K Current Event Report Filed 2019-01
    SECURITIES AND EXCHANGE COMMISSION FORM 8-K Current report filing Filing Date: 2019-01-07 | Period of Report: 2019-01-07 SEC Accession No. 0001628280-19-000132 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 8-K | Act: 34 | File No.: 001-38683 | Film No.: 19512177 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2019 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 0001-576280 45-4139254 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation or organization) File Number) Identification No.) 505 Penobscot Dr. Redwood City, California 94063 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under
    [Show full text]
  • Guardant Health, Inc. Form 10-Q Quarterly Report Filed 2021-08-05
    SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Quarterly report pursuant to sections 13 or 15(d) Filing Date: 2021-08-05 | Period of Report: 2021-06-30 SEC Accession No. 0001576280-21-000080 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 10-Q | Act: 34 | File No.: 001-38683 | Film No.: 211148786 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware 45-4139254 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 505 Penobscot Dr. Redwood City, California, 94063 Registrant’s telephone number, including area code: (855) 698-8887 _______________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Monitoring Trace Levels of Ctdna Using Integration of Variant Reads
    Monitoring trace levels of ctDNA using 1 integration of variant reads 2 3 Jonathan C. M. Wan 4 Supervisor: Dr Nitzan Rosenfeld 5 6 Cancer Research UK Cambridge Institute 7 8 University of Cambridge This dissertation is submitted for the degree of 9 Doctor of Philosophy 10 Trinity College May 2019 11 Abstract 12 In patients with early-stage cancer, ctDNA detection rates can be low due to the presence of 13 few or no copies of any individual mutation in each sample. Sensitivity may be increased 14 by collecting larger plasma volumes, but this is not feasible in practice. Although cancers 15 typically have thousands of mutations in their genome, previous analyses measured only 16 individual or up to 32 tumour-specific mutations in plasma. 17 Here, we demonstrate that sensitivity can be greatly enhanced for any given input DNA 18 mass by analysing a large number of mutations via sequencing. We sequenced in plasma 2 4 19 10 -10 mutated loci per patient, using custom capture panels, whole exome (WES) or 20 whole genome sequencing (WGS). We developed a method for INtegration of VAriant Reads 21 (INVAR) that aggregates reads carrying tumour mutations across multiple mutant loci, and 22 assigns confidence to error-suppressed reads based on mutation context, fragment length and 23 tumour representation. This workflow combines a number of concepts in a novel approach in 24 order to quantify ctDNA with maximal sensitivity. 25 We applied INVARto plasma sequencing data from 45 patients with stage II-IV melanoma 26 and 26 healthy individuals. ctDNA was detected to 1 mutant molecule per million, and tu- 3 27 mour volumes of ~1cm .
    [Show full text]
  • Liquid Biopsy Is at the Core of Our Mission to Conquer Cancer with Data
    guardanthealth.com • [email protected] • +1.812.731.2203 CORPORATE BACKGROUNDER LIQUID BIOPSY IS AT THE CORE OF OUR MISSION TO CONQUER CANCER WITH DATA Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets, and advanced analytics. A company uniquely positioned to help patients across the entire cancer care continuum At Guardant Health, we believe liquid biopsy is at the center of transforming cancer care by unlocking data that will help patients at all stages of the disease. While we’ve made great strides to help advanced cancer patients, our vision since inception has been to detect cancer early, when patient survival rates can be impacted most. We are dedicated to helping patients across the cancer care continuum live longer, healthier lives. 700K+ 15M+ 65M+ Advanced Cancer Early-Stage Patients Asymptomatic and Patients and Survivors High Risk Screening Guardant360® CDx liquid biopsy LUNAR-1 program (in development) LUNAR-2 program (in development) (Estimated number of patients in the US) Guardant360® CDx liquid biopsy is poised to bring the promise of precision oncology to more patients Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling (CGP) in advanced cancer patients across all solid cancers, and for use as a companion diagnostic for patients who may benefit from Tagrisso® (osimertinib). We believe the ease of our blood test together with approval will help widen adoption of CGP and enable more patients to receive potentially life-changing precision medicines. In 2014, we introduced the Guardant360 laboratory developed test (LDT), the first-in-kind liquid biopsy to comprehensively sequence a patient's cancer to reveal actionable mutations.
    [Show full text]
  • Prospective Blinded Study of Somatic Mutation Detection in Cell-Free DNA Utilizing a Targeted 54-Gene Next Generation Sequencing
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 37 Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Seung Tae Kim1,*, Won-Suk Lee2,*, Richard B. Lanman3, Stefanie Mortimer3, Oliver A. Zill3, Kyoung-Mee Kim4,5, Kee Taek Jang5, Seok-Hyung Kim5, Se Hoon Park1, Joon Oh Park1,4, Young Suk Park1, Ho Yeong Lim1, Helmy Eltoukhy3, Won Ki Kang1, Woo Yong Lee6, Hee-Cheol Kim6, Keunchil Park1,4, Jeeyun Lee1,4, AmirAli Talasaz3 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Department of Surgery, Gil Medical Center, Gachon University, School of Medicine, Incheon, Korea 3 Guardant Health Inc., Redwood City, CA, USA 4 The Innovative Cancer Medicine Institute, Samsung Medical Center, Seoul, Korea 5 Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 6 Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea *These authors have contributed equally to this work Correspondence to: Jeeyun Lee, e-mail: [email protected] AmirAli Talasaz, e-mail: [email protected] Keywords: cell-free DNA (cfDNA), digital sequencing, genomic test Received: July 31, 2015 Accepted: September 24, 2015 Published: October 05, 2015 ABSTRACT Sequencing of the mutant allele fraction of circulating cell-free DNA (cfDNA) derived from tumors is increasingly utilized to detect actionable genomic alterations in cancer. We conducted a prospective blinded study of a comprehensive cfDNA sequencing panel with 54 cancer genes. To evaluate the concordance between cfDNA and tumor DNA (tDNA), sequencing results were compared between cfDNA from plasma and genomic tumor DNA (tDNA).
    [Show full text]
  • The Top 50 Healthcare Technology Ceos of 2021
    The Top 50 Healthcare Technology CEOs Of 2021 April 14, 2021 The Healthcare Technology Report is pleased to announce the Top 50 Healthcare Technology CEOs of 2021. This year’s awardees represent some of the most accomplished executives in healthcare technology. Their leadership has been critical in developing industry leading medical devices, next generation software platforms, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies. Notably, in addition to overseeing their companies’ efforts from the C-suite, many of these leaders were also founders or co-founders of their organizations, recognizing unique opportunities for transformation and growth within their areas of expertise. From inventing novel orthopedic and mobility devices, to spearheading platforms to strengthen the patient/provider connection, and to developing new blood tests to diagnose diseases, these awardees have made significant contributions to society at large. They come from varied backgrounds in medicine, research, biotechnology, business, and finance, leveraging unique insights to provide their companies with the agility and ingenuity needed to thrive. While highly involved and instrumental to the continued success of their companies, they have also remained dedicated to advancing their particular fields, with many participating in prestigious research institutions and trade groups that are collaborating to develop more effective solutions for patients across the globe. Please join us in honoring The Top 50 Healthcare Technology CEOs of 2021. The Healthcare Technology Report https://thehealthcaretechnologyreport.com/the-top-50-healthcare-technology-ceos-of-2021/ 1. Geoff Martha Company: Medtronic Title: Chairman of the Board of Directors and Chief Executive Officer Geoff Martha is Chairman of the Board of Directors and Chief Executive Officer at Medtronic.
    [Show full text]
  • The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California
    The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California Presented in partnership with AAAS/Science Translational Medicine Course Introduction Conference Highlights • Voice of the patient represented Course Overview throughout the conference In collaboration with AAAS/Science Translational Medicine we invite you to • Renowned faculty representing the another exciting two day program on Thursday, March 3 and Friday, March country’s leading institutions • Multiple panel discussion segments 4, 2016 in beautiful San Diego, California. The 2016 program will again be with ample question and answer time with faculty held at Scripps Institution of Oceanography. • Additional networking opportunities The 9th Future of Genomic Medicine conference will be the next iteration Educational Objectives of taking genomic knowledge to transform the daily practice of medicine. After attending this activity, participants should be able to: To do this, we have patients present their story of how genomics affected • Demonstrate the unmet needs of their medical status, and have an international faculty of experts in genomics, medicine today with respect to more targeted, individualized prevention science and medical journalism, and the life science industry provide critical and treatments. perspective. This year we will be paying particular attention to the exciting • Discuss the opportunities of the genome, proteome, metabolome area of genomic editing to treat particular diseases, cancer (a disease of the discovery to change medical practice as it exists today. genome), and the genomics of rare and unknown diseases. Furthermore, we • Assess how changes and advances in will delve into to the hot topics of the microbiome, genomic-guided drug technology are rapidly ushering in a whole array of new pathways for therapies and genomic analytics.
    [Show full text]
  • Guardant Health Q3 2020 Earnings Call
    Guardant Health Third Quarter 2020 Earnings Call November 5, 2020 Guardant Health – Third Quarter 2020 Earnings Call, November 5, 2020 C O R P O R A T E P A R T I C I P A N T S Carrie Mendivil, Investor Relations - Gilmartin Group Helmy Eltoukhy, Co-founder and Chief Executive Officer AmirAli Talasaz, Co-founder and President Derek Bertocci, Chief Financial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Puneet Souda, SVB Tycho Peterson, JPMorgan Doug Schenkel, Cowen Derik de Bruin, Bank of America Brian Weinstein, William Blair Patrick Donnelly, Citigroup Tejas Savant, Morgan Stanley Sung Ji Nam, BTIG P R E S E N T A T I O N Operator Ladies and gentlemen, thank you for standing by, and welcome to the Guardant Health Q3 2020 Earnings Call. At this time all participants are in a listen-only-mode. After the speaker’s presentation, there will be a question-and-answer session. To ask a question during the session, you need to press star, one on your telephone. If you wish to withdraw your question, press the pound key. I would now like to turn the conference over to your speaker today, Carrie Mendivil with Investor Relations. You may begin. Carrie Mendivil 1 ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.
    [Show full text]
  • Guardant Steps Into a New Arena
    June 22, 2021 Guardant steps into a new arena Elizabeth Cairns A test that tracks response to therapy is useful, but approval and reimbursement will be key. One of the groups locked in battle for dominance of the pan-cancer blood test market has just pulled ahead in a new setting. Today Guardant Health launched in the US what it claims is the first liquid biopsy that can track a patient’s response to immunotherapy or targeted drugs, and do so more quickly than current methods used by oncologists. Questions remain, notably around pricing and reimbursement. Given that the Guardant360 Response test will have to be administered repeatedly, costs could mount up fast. But the existing approved tumour-agnostic liquid biopsies are seeing increased acceptance, so Guardant360 Response could find a market – though formal FDA approval would probably be a necessary step to get payers on board. Guardant360 Response, launched in the US as a lab-developed test, can pinpoint the levels of circulating tumour DNA (ctDNA) in a patient’s blood; by tracking how these fluctuate it can determine whether the patient is responding to their prescribed drug regimen. This is a different setting from the group’s only FDA-approved test, Guardant360 CDx, which is used to profile a patient’s tumour biomarkers. Guardant360 Response is believed to test for 74 genetic mutations, whereas Guardant360 CDx is more comprehensive. Guardant Health's liquid biopsies Test Setting Status Launched as LDT May Guardant360 Pan-cancer; helps assign targeted therapy 30, 2014 Guardant360 CDx Pan-cancer; helps assign targeted therapy Approved Aug 7, 2020 Guardant360 Launched as LDT Jun Pan-cancer; tracks response to targeted or immunotherapy Response 22, 2021 Guardant360 Pan-cancer tissue test; helps assign targeted therapy – to be Launched as LDT Jun TissueNext* ordered at same time as Guardant360 CDx 22, 2021 Pan-cancer; sold to biopharma companies to aid drug Launched in 2017 for GuardantOMNI development.
    [Show full text]
  • Moneyball Medicine Discusses Some of the Remarkable Innovations That Are Developing Across the Healthcare Industry
    MoneyBall Medicine discusses some of the remarkable innovations that are developing across the healthcare industry. Harry and Malorye provide readers with a front row seat to the most important emerging healthcare system challenges—and opportunities—of our time. We started Flatiron because we wanted to ensure that all cancer patients—not just those with the means and resources—have access to the same cutting-edge research. It is our hope that this book will stimu- late discussions around the value of next-generation technology in healthcare so that the industry can continue to innovate. Zach Weinberg Cofounder, COO, and President Flatiron Health MoneyBall Medicine puts you at the center of healthcare’s new frontier where medicine, tech- nology, information, and business are converging and advancing with unprecedented speed and importance. The stakes could not be higher, and I recommend this book for anyone interested in learning more about this truly disruptive revolution in the ever-changing healthcare landscape. Eric Schadt, PhD Dean for Precision Medicine, Mount Sinai Health System Professor, Genetics and Genomic Sciences at Mount Sinai The political turbulence focused on what comes next for Medicaid, Medicare, and the Affordable Care Act (Obamacare) public exchange products simply reinforces the fundamentals of healthcare in the United States. Increased access, increased value, and better patient experience will be keys for all successful stakeholders. In MoneyBall Medicine, Harry and Malorye describe the unique confluence of entrepreneurial innovation and the many entrenched and evolving healthcare components of the healthcare supply chain, and defines the parameters that predict who will win and who will lose.
    [Show full text]
  • Never Lose Hope Page
    Fertility after cancer treatment P.10-11 Never Lose Hope Six-year-old Jasmine was diagnosed with acute lymphoblastic leukaemia last year. Here, Jasmine’s mum Karen shares her daughter’s story. Page 8-9 Nurse service on the help line now available Monday – Friday. Call Freephone 08088 010 444. SUMMER EDITION 2017 www.leukaemiacare.org.uk In This Issue... P.4 News Catch up on the latest news from our Campaigns and Advocacy team P.7 Kris is WIRED at Executive Health Conference Trustee Kris discovers up and coming treatments for blood cancer at WIRED Health P.10 Fertility after cancer treatment How can treatment affect your fertility? P.12 Karen Orwin’s Story P.8 Read how Karen defied the odds Jasmine’s Story P.13 Fundraising news See what our fundraisers have been up to P.10 Fertility Feature P.14 Radiotherapy - what’s it all about? Learn the ins and outs of radiotherepy P.7 P.16 Clinical trials: what are they? Kris is WIRED Our Nurse Advisor, Angela gives an insight into how clinical trials work P.16 P.18 Clinical Trials Support P.18 Support group spotlight Group Our Liverpool support group has been busy P.19 London Marathon Find out what happened on the big day Hello, P.12 This Summer edition is packed full of informative Karen Orwin’s articles and inspiring patient stories. We have all Story you need to know about clinical trials, as well as a spotlight on our longest running support group. Our Campaigns and Advocacy team are also on hand to update you on the latest news, along with a feature on our new report.
    [Show full text]
  • The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
    Author Manuscript Published OnlineFirst on May 18, 2018; DOI: 10.1158/1078-0432.CCR-17-3837 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients Oliver A. Zill, PhD1,†, Kimberly C. Banks, MS, MBA1, Stephen R. Fairclough, PhD1,*, Stefanie A. Mortimer, PhD1, James V. Vowles, PhD1, Reza Mokhtari, MS1, David R. Gandara, MD2, Philip C. Mack, PhD2, Justin I. Odegaard, MD, PhD1, Rebecca J. Nagy, MS1, Arthur M. Baca, MD, PhD1, Helmy Eltoukhy, PhD1, Darya I. Chudova, PhD1, Richard B. Lanman, MD1, AmirAli Talasaz, PhD1 1 Guardant Health, Inc., Redwood City, CA, 94063, USA. 2 University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA. † Present address: Department of Bioinformatics and Computational Biology, Genentech, 1 DNA Way, South San Francisco, California 94080, USA. Running title: Somatic genomic landscape of circulating tumor DNA Keywords: circulating tumor DNA, tumor heterogeneity, resistance, genomic landscape, cfDNA clonality Financial support: The study was funded by and conducted at Guardant Health, Inc. No additional grant support or administrative support was provided for the study. *Corresponding author: Stephen R. Fairclough, PhD 505 Penobscot Dr, Redwood City, CA 94063 Email: [email protected] Phone: (855) 698-8887 Conflict of interest statement: All authors except Dr. Mack and Dr. Gandara are paid employees and/or stockholders of Guardant Health, Inc. Dr. Mack has received honoraria from Guardant Health. Dr. Gandara has no financial relationships to disclose. Word count: 4,707 Total number of figures and tables: 6 Downloaded from clincancerres.aacrjournals.org on September 27, 2021.
    [Show full text]